Deqing, China, July 19, 2018 / B3C newswire / -- Following a 2016 accreditation of Shuwen Biotech’s central lab, Shuwen Guanz Diagnostic Lab Co., Ltd, Shuwen is proud to announce that it has successfully passed the 2018 biannual review and was awarded a two-year extension of the CAP accreditation.
Certification from The College of American Pathologists (CAP) is recognized as the global standard for laboratory quality management and technology in various international medical organizations, and has become the "gold standard" in the field of international laboratory medicine. Reports issued by CAP-certified laboratories meet US FDA requirements in the regulatory processes for new drugs to be marketed in the United States.
About Shuwen Biotech
Shuwen Biotech is a China-based diagnostic company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen established strategic partnerships with numerous outstanding academic and commercial institutions such as Yale University, University of Chicago, BioNTech, Sphingotec among others in the form of exclusive licensing of first-in-class diagnostic technologies and patents covering a range of novel biomarkers for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, and health screening and other fields. Shuwen has also developed innovative and quality companion diagnostics and provided central lab testing services to leading pharmaceutical developers. Shuwen houses an in-house development team, CAP-accredited central labs, and ISO13485-certified IVD manufacturing facilities, all in line with global standards in order to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health.